drugset
drugset / Trial / NCT04234048

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048 ↗

Phase 1 Recruiting 46 enrolled SciTech Development, Inc.
NaSequentialOpen-labelTreatment

Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

Timeline

Start
2023-12-18
Primary completion
2026-12-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 1.25 mg/m2 Intravenous
Subject fenretinide Small molecule 2.5 mg/m2 Intravenous
Subject fenretinide Small molecule 5 mg/m2 Intravenous
Subject fenretinide Small molecule 10 mg/m2 Intravenous
Subject fenretinide Small molecule 20 mg/m2 Intravenous
Subject fenretinide Small molecule 40 mg/m2 Intravenous
Subject fenretinide Small molecule 80 mg/m2 Intravenous
Subject fenretinide Small molecule 160 mg/m2 Intravenous
Subject fenretinide Small molecule 320 mg/m2 Intravenous
Subject fenretinide Small molecule 640 mg/m2 Intravenous
Subject fenretinide Small molecule 896 mg/m2 Intravenous
Subject fenretinide Small molecule 1254 mg/m2 Intravenous
Subject fenretinide Small molecule 1756 mg/m2 Intravenous

Indications

Nodal T-follicular helper cell lymphoma, follicular type Sezary syndrome angioimmunoblastic T-cell lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified